The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked CRA to evaluate the policies that host governments of middle-income countries use to encourage investment in innovative activities and the implications for future innovation. CRA consultants looked at eight countries and concluded that there are six key lessons that appear to be critical for success. Read more in the article here:
CRA presents at AXS25 "GLP-1s: Riding the Wave of Innovative Medications"
Read the key takeaways here.